Volume 25, Number 10—October 2019
Dispatch
Tick-Borne Encephalitis in Auvergne-Rhône-Alpes Region, France, 2017–2018
Table 1
Characteristic | Case-patient 1 | Case-patient 2 | Case-patient 3 |
---|---|---|---|
Medical history |
Myelofibrosis associated with a JAK 2 mutation, treated with hydroxicarbamide |
None |
Zoster Bell palsy in 1990, arterial hypertension, obesity (BMI 34 kg/m2) |
Outdoor activity | |||
Date/duration | 2017 Jun 2/2 d | 2017 Aug 13–19 | All year |
Location | Allègre region (43270, Haute Loire) | Montarcher forest (42380, Loire) | Saint-Bonnet-le-Courreau (42940, Loire) |
Type |
Hiking for 10 km |
Hiking, camping |
Farming |
Tick exposure |
3 nonidentified insect bites on legs and left arm (no eschar, slight erythema at localizations of bites) while hiking |
1 tick bite; tick removed 48 h later |
Yes, frequent |
Clinical manifestations | |||
Date of symptom onset | 2017 Jun 17 | 2017 Aug 30 | 2018 Jul 21 |
Main clinical signs | Headache, left cervicobrachial neuralgia, asthenia, delayed persistent fever (>38.5°C) | Low-grade fever (38.5°C), headache, cervical pain, nausea, vomiting | Dizziness, headache, fever (38.4°C), unable to lift right shoulder |
Physical findings | No abnormality | Neck stiffness | Proximal deficit in right arm; 3 days later, light deficit in right leg, inability to walk because of motor deficit and dizziness |
Encephalitis |
No |
No |
Yes |
Radiologic findings |
Unremarkable cerebral CT scan |
None |
Unremarkable cerebral CT scan and cerebral MRI |
Biological parameters | |||
CSF analysis | 2017 Jun 23 | 2017 Sep 2 | 2018 Jul 21 (first one) |
Leukocytes, cells/mm3 | 5 | 62 (50% PMNs) | 195 (88% lymphocytes) |
Erythrocytes, cells/mm3 | 2 | 1 | 51 |
Proteinorachia, g/L | 0.67 | 0.48 | 0.77 |
Glycorachia/glycemia, mmol/L |
2.98/5.8 |
3.4/5.6 |
3.18/5.68 |
Etiologic investigations |
Absence of HSV, VZV, or enterovirus by PCR or RT-PCR; presence of TBEV IgM |
Absence of enterovirus by RT-PCR; presence of TBEV IgM |
Absence of HSV, VZV, or enterovirus by PCR or RT-PCR; presence of Borrelia burgdorferi IgG in CSF; Reiber index <2; presence of TBEV IgM |
Blood analyses |
Blood serology negative for Mycoplasma pneumonia, Bartonella henselae, Coxiella burnetii, Legionella pneumophila, HIV, hepatitis B and C viruses, B. burgdorferi (both in serum and CSF); positive for cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, and Chlamydia pneumophila, revealed past immunization |
None |
Blood serology for B. burgdorferi IgG >0; blood serology negative for M. pneumonia, B. henselae, C. burnetii, L. pneumophila, HIV, hepatitis B and C viruses |
Treatment |
2017 Jun 17: paracetamol; 2017 Jun 19: ceftriaxone 1 g/d + levofloxacin 1 g/d; 2017 Jun 23: treatment stopped |
2017 Feb 17: ceftriaxone 100 mg/kg/d; 2017 Sep 4: ceftriaxone stopped, switched to doxycycline 200 mg/d |
2018 Jul 21: acyclovir 3,000 mg/d amoxicillin 12 g/d; 2018 Jul 27: acyclovir stopped, amoxicillin switched to ceftriaxone 2 g/d for 14 d |
Outcome |
Headache and asthenia waned progressively, fever disappeared; discharged 2017 Jun 29 |
Discharge 2017 Sep 4 |
Discharged 2018 Aug 17 to rehabilitation center because of persistent dizziness and motor deficit in right arm and leg |
Follow-up |
Consultation 2017 Jul 27; patient felt good, no headache or fever |
Consultation 2017 Sep 18: complete recovery |
Consultation 2018 Sep 19; patient able to walk alone but always with a slight motor deficit of right arm and leg and dizziness |
Sequelae | No | No | Yes |
*Case-patient 1, 76-year-old man; case-patient 2, 8-year-old boy; case-patient 3, 66-year-old woman. No patients had been vaccinated against arboviruses. BMI, body mass index; CSF, cerebrospinal fluid; CT, computed tomography; HSV, herpes simplex virus; MRI, magnetic resonance imaging; PMN, polymorphonuclear cell; RT-PCR, reverse transcription PCR; TBEV, tick-borne encephalitis virus; VZV, varicella zoster virus.
Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.